Optimizing management of hypertension with combination therapy: Considerations for the nurse practitioner

Journal of Cardiovascular Nursing

Volumn 24, Issue 5, 2009, Pages 380-389

  Roberts, Mary Ellen ^a   Epstein, Benjamin J ^b,c  

^a Clinical and Invasive Cardiology PA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c East Coast Institute for Research   (United States)

Author keywords

Antihypertensives; Calcium channel blockers; Combination therapy; Edema; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; EDEMA; HUMAN; HYPERTENSION; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EDEMA; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; NURSE PRACTITIONERS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; RENIN-ANGIOTENSIN SYSTEM; RISK REDUCTION BEHAVIOR;

EID: 70249106107     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e3181aed18e     Document Type: Article

References (71)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252.
2. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
3. Multiple Risk Factor Intervention Trial Research Group. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Prev Med. 1986;15(3):254-273.
4. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112(22):3384-3390.
5. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13(1 pt 2):3SY10S.
6. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536.
7. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-1297.
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349): 1903-1913.
9. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6): 791-798.
10. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framing-ham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20-24.
11. Margolis KL, Rolnick SJ, Fortman KK, et al. Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. Am J Hypertens. 2005;18(4 pt 1):566-571.
12. Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. 2004;117(1):14-18.
13. Simpson RJ Jr. Challenges for improving medication adherence. JAMA. 2006;296(21):2614-2616.
14. Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
15. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-1152.
16. Dennison CR, Houston Miller N. Adherence to antihy-pertensive therapy. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer. 4th ed. American Heart Association; 2008:413-417.
17. Rudd P, Miller NH, Kaufman J, et al. Nurse management for hypertension. A systems approach. Am J Hypertens. 2004;17(10):921-927.
18. Enhancing Prescription Medicine Adherence: A National Action Plan. Bethesda, MD: National Council on Patient Information and Education; 2007.
19. Fiscella K, Holt K. Racial disparity in hypertension control: tallying the death toll. Ann Fam Med. 2008;6(6):497-502.
20. Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension. 2004;43(3):566-572.
21. Lecheminant JD, Kirk EP, Hall MA, et al. Impact of different levels of weight loss on blood pressure in overweight and obese women. Dis Manag. 2007;10(2):83-90.
22. Berger BA, Felkey BG, Krueger KP. The pharmacist's role in treatment adherence, part 3: applying motivational interviewing principles. US Pharm. 2005;3:38-47.
23. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311): 995-1003. (Pubitemid 34286536)
25. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998; 351:1755-1762. (Pubitemid 28269185)
26. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009; 53(4):646-653.
27. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
28. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16(2):80-86.
29. Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens. 2008;21(10):1076-1085.
30. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25(5):1034-1041.
31. Williams B, O'Rourke M. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT. J Hum Hypertens. 2001;15(suppl 1):S69-S73.
32. Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7(10):578-586.
33. Dahlof B, Gosse P, Gueret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens. 2005;23(11):2063-2070.
34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290(21):2805-2816.
35. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404): 1427-1434.
36. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002; 62(3):443-462.
37. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hyper-tens. 2005;19(6):491-496.
38. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
39. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10(7 pt 1):697-704.
40. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ. 2001;323(7305):142-146. (Pubitemid 32678389)
41. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macro-vascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840.
42. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
43. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
44. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117(3):234-242.
45. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190-198.
46. Wright JT, Davis BR. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 2981-2997.
47. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med. 1998;158(7):741-751.
48. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2001;23(6):833-850.
49. Pool JL, Glazer R, Weinberger M, et al. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007; 29(1):61-73.
50. Bakris G, Molitch M, Zhou Q, et al. Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008;3(1):18-25.
51. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364(9446): 1684-1689.
52. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496): 1545-1553.
53. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52:1482-1489.
54. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol. 2008;52(13):1062-1072.
55. Messerli FH. Evolution of calcium antagonists: past, present, and future. Clin Cardiol. 2003;26(2 suppl 2): II12-II16.
56. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003; 5(5):330-335.
57. Cho S, Atwood JE. Peripheral edema. Am J Med. 2002; 113(7):580-586.
58. Schroth BE. Evaluation and management of peripheral edema. JAAPA. 2005;18(11):29-34.
59. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14(9 pt 1): 978-979.
60. Sica DA. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich). 2003;5(4):291-294, 297.
61. Chrysant SG, Sugimoto DH, Lefkowitz M, et al. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Blood Press. 2007;16(suppl 1):10-17.
62. Fogari R, Malamani GD, Zoppi A, et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2003;17(3):207-212.
63. Mohler ER 3rd, Herrington D, Ouyang P, et al. A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure. J Clin Hypertens (Greenwich). 2006;8(10):692-698.
64. Neutel JM, Smith DH, Weber MA, et al. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol. 2006;15(3): 142-150.
65. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens. 2008;2(4):294-302.
66. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220-224.
67. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580.
68. Schrader J, Weisskopf M, Keeling L, Ferber P. The combination of amlodipine/valsartan (5/160 mg) significantly reduces the incidence of peripheral edema versus amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. J Hypertens. 2008;26(suppl 1):S478. 69.
69. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-604.
70. Flack JM, Calhoun DA, Satlin L, Barbier M, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine mono-therapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23(7):479-489.
71. Garber AJ, Handelsman Y, Bergman DA, et al. American College of Endocrinology consensus statement on the diagnosis and management of pre-diabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? American College of Endocrinology Task Force on Pre-Diabetes; July 23, 2008.